To evaluate target validation in our in vivo studies, we examined GS protein expression in GS shRNA-expressing tumors compared to shControl tumors, and we also examined changes in serum and tumor glutamate/glutamine in response to MSO treatment. The gene discussed is GLUL; the disease is neoplasm.